Russell Investments Group Ltd. Has $8.03 Million Stake in Geron Co. (NASDAQ:GERN)

Russell Investments Group Ltd. trimmed its stake in shares of Geron Co. (NASDAQ:GERN - Free Report) by 8.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,267,808 shares of the biopharmaceutical company's stock after selling 221,453 shares during the period. Russell Investments Group Ltd. owned about 0.38% of Geron worth $8,028,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd increased its position in shares of Geron by 158.5% in the fourth quarter. Dynamic Technology Lab Private Ltd now owns 109,651 shares of the biopharmaceutical company's stock worth $388,000 after acquiring an additional 67,230 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Geron by 22.3% in the fourth quarter. Wells Fargo & Company MN now owns 392,696 shares of the biopharmaceutical company's stock valued at $1,390,000 after purchasing an additional 71,697 shares in the last quarter. ExodusPoint Capital Management LP acquired a new stake in shares of Geron in the fourth quarter worth $377,000. Headlands Technologies LLC grew its holdings in shares of Geron by 20,112.6% during the fourth quarter. Headlands Technologies LLC now owns 218,700 shares of the biopharmaceutical company's stock valued at $774,000 after buying an additional 217,618 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Geron by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 13,141,514 shares of the biopharmaceutical company's stock worth $46,531,000 after acquiring an additional 73,515 shares during the period. Hedge funds and other institutional investors own 73.71% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on GERN. B. Riley lowered shares of Geron from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $3.50 to $2.00 in a research note on Thursday, February 27th. HC Wainwright reaffirmed a "neutral" rating on shares of Geron in a research note on Wednesday, March 12th. Scotiabank reduced their price target on Geron from $6.00 to $4.00 and set a "sector outperform" rating for the company in a report on Thursday, February 27th. Stifel Nicolaus reduced their target price on shares of Geron from $8.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, February 27th. Finally, Barclays restated an "overweight" rating and set a $4.00 price target (down previously from $9.00) on shares of Geron in a research note on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $5.75.

Geron Stock Performance

Shares of GERN stock traded up $0.03 during trading hours on Thursday, reaching $1.27. 8,281,957 shares of the company's stock were exchanged, compared to its average volume of 11,441,825. The business has a fifty day moving average price of $1.83 and a 200-day moving average price of $3.07. The stock has a market capitalization of $808.88 million, a P/E ratio of -3.97 and a beta of 0.66. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. Geron Co. has a fifty-two week low of $1.17 and a fifty-two week high of $5.34.

Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). The firm had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. Analysts predict that Geron Co. will post -0.25 EPS for the current fiscal year.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.